Futibatinib: paving the way to personalized medicine in intrahepatic cholangiocarcinoma

References

• 1. Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise. Oncologist 21(5), 594–599 (2016).
  MedlineGoogle Scholar
• 2. Florio AA, Ferlay J, Znaor A et al. Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012. Cancer 126(11), 2666–2678 (2020).
  MedlineGoogle Scholar
• 3. Jusakul A, Cutcutache I, Yong CH et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 7(10), 1116–1135 (2017).
  Medline CASGoogle Scholar
• 4. Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
  MedlineGoogle Scholar
• 5. Banales JM, Marin JJG, Lamarca A et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat. Rev. Gastroenterol. Hepatol. 17(9), 557–588 (2020).
  MedlineGoogle Scholar
• 6. Massarweh NN, El-Serag HB. Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control 24(3), 1073274817729245 (2017).
  Google Scholar
• 7. Oh D-Y, Ruth He A, Qin S et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 1(8), EVIDoa2200015 (2022).
  MedlineGoogle Scholar
• 8. Lamarca A, Palmer DH, Wasan HS et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 22(5), 690–701 (2021).
  Medline CASGoogle Scholar
• 9. Arai Y, Totoki Y, Hosoda F et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology 59(4), 1427–1434 (2014).
  Medline CASGoogle Scholar
• 10. Farshidfar F, Zheng S, Gingras M-C et al. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep. 18(11), 2780–2794 (2017).
  Medline CASGoogle Scholar
• 11. Krook MA, Reeser JW, Ernst G et al. Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance. Br. J. Cancer 124(5), 880–892 (2021).
  Medline CASGoogle Scholar
• 12. Abou-Alfa GK, Sahai V, Hollebecque A et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 21(5), 671–684 (2020).
  Medline CASGoogle Scholar
• 13. Javle M, Lowery M, Shroff RT et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J. Clin. Oncol. 36(3), 276–282 (2018).
  Medline CASGoogle Scholar
• 14. Abou-Alfa GK, Borbath I, Goyal L et al. PROOF 301: a multicenter, open-label, randomized, phase 3 trial of infigratinib versus gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement. JCO 40(Suppl. 16), TPS4171–TPS4171 (2022).
  Google Scholar
• 15. Mauro E, Ferrer-Fàbrega J, Sauri T et al. New challenges in the management of cholangiocarcinoma: the role of liver transplantation, locoregional therapies, and systemic therapy. Cancers (Basel) 15(4), 1244 (2023).
  Medline CASGoogle Scholar
• 16. Sootome H, Fujita H, Ito K et al. Futibatinib is a novel irreversible FGFR 1–4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors. Cancer Res. 80(22), 4986–4997 (2020).
  Medline CASGoogle Scholar
• 17. Bahleda R, Meric-Bernstam F, Goyal L et al. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors. Ann. Oncol. 31(10), 1405–1412 (2020).
  Medline CASGoogle Scholar
• 18. Doi T, Shitara K, Kojima T et al. Phase I study of the irreversible fibroblast growth factor receptor 1–4 inhibitor futibatinib in Japanese patients with advanced solid tumors. Cancer Sci. 114(2), 574–585 (2023).
  Medline CASGoogle Scholar
• 19. Goyal L, Meric-Bernstam F, Hollebecque A et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N. Engl. J. Med. 388(3), 228–239 (2023).
  Medline CASGoogle Scholar